Prognostic significance of NANOG expression in solid tumors: a meta-analysis
NANOG is a tumor marker and indicates poor prognosis in various neoplasms; however, the evidence is controversial. This meta-analysis investigated the association of NANOG expression and clinicopathological features, and it impact on survival of patients with malignant tumors. Studies published thro...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2018-01, Vol.11, p.5515-5526 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5526 |
|---|---|
| container_issue | |
| container_start_page | 5515 |
| container_title | OncoTargets and therapy |
| container_volume | 11 |
| creator | Zhao, Lingqiong Liu, Jie Chen, Shu Fang, Chun Zhang, Xianquan Luo, Zhibin |
| description | NANOG is a tumor marker and indicates poor prognosis in various neoplasms; however, the evidence is controversial. This meta-analysis investigated the association of NANOG expression and clinicopathological features, and it impact on survival of patients with malignant tumors.
Studies published through May 31, 2018 were retrieved from PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure. Two researchers independently screened the content and quality of studies and extracted data. Correlations of NANOG expression, clinicopathological variables, and survival were analyzed and the combined odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated.
Thirty-three articles including 35 data sets of 3,959 patients were analyzed. Overall, elevated NANOG expression was associated with poor overall survival (HR = 2.19; 95% CI: 1.87-2.58, |
| doi_str_mv | 10.2147/OTT.S169593 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6134963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A583694982</galeid><sourcerecordid>A583694982</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-eb55469719d54ba18515f2fba9c63f05911fe03fb4d185db28bf7e7567cdb2143</originalsourceid><addsrcrecordid>eNptkl1rFDEUhgdRbK1eeS8BoQgy6-RzJl4UllJbYekKrtchkznZTZlJ1mRG7L9vSrfLrphc5OM85w055y2K97iaEczqL8vVavYTC8klfVGcYlw3pZC0enmwPynepHRXVUI0hL0uTmhFKCWYnhaLHzGsfUijMyi5tXfWGe0NoGDR7fx2eY3g7zZCSi545DxKoXcdGqchxPQVaTTAqEvtdX-fXHpbvLK6T_But54Vv75drS5vysXy-vvlfFEaXtOxhJZzJmSNZcdZq3HDMbfEtloaQW3FJcYWKmpb1uVY15KmtTXUXNQmHzCjZ8XFk-52agfoDPgx6l5toxt0vFdBO3Uc8W6j1uGPEpgyKWgW-LQTiOH3BGlUg0sG-l57CFNSBOfBOKY4ox__Qe_CFPOHM0UYbkRDs-KeWuselPM25HfNo6ia84YKyWRDMjX7D5VnB4MzwYN1-f4o4fwgYQO6Hze5A9OYu5GOwc9PoIkhpQh2XwxcqUeXqOwStXNJpj8c1m_PPtuCPgARC7Vp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2241868396</pqid></control><display><type>article</type><title>Prognostic significance of NANOG expression in solid tumors: a meta-analysis</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Zhao, Lingqiong ; Liu, Jie ; Chen, Shu ; Fang, Chun ; Zhang, Xianquan ; Luo, Zhibin</creator><creatorcontrib>Zhao, Lingqiong ; Liu, Jie ; Chen, Shu ; Fang, Chun ; Zhang, Xianquan ; Luo, Zhibin</creatorcontrib><description>NANOG is a tumor marker and indicates poor prognosis in various neoplasms; however, the evidence is controversial. This meta-analysis investigated the association of NANOG expression and clinicopathological features, and it impact on survival of patients with malignant tumors.
Studies published through May 31, 2018 were retrieved from PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure. Two researchers independently screened the content and quality of studies and extracted data. Correlations of NANOG expression, clinicopathological variables, and survival were analyzed and the combined odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated.
Thirty-three articles including 35 data sets of 3,959 patients were analyzed. Overall, elevated NANOG expression was associated with poor overall survival (HR = 2.19; 95% CI: 1.87-2.58,
<0.001) and poor disease-free survival (HR = 2.21, 95% CI: 1.54-3.18,
<0.001). Subgroup analysis found that NANOG expression was associated with worse overall survival in non-small cell lung (HR = 1.87; 95% CI: 1.26-2.76,
= 0.002), head and neck (HR = 2.29; 95% CI: 1.75-3.02,
<0.001), and digestive system (HR = 2.38; 95% CI: 1.95-2.91,
<0.001) cancers. Moreover, we found that high NANOG expression was associated with poor tumor differentiation (OR = 2.63; 95% CI: 1.59-4.55,
= 0.001), lymph node metastasis (OR = 2.59; 95% CI: 1.50-4.47,
= 0.001), advanced TNM stage (OR = 2.22; 95% CI: 1.42-3.45,
<0.001), and T stage (OR = 0.44; 95% CI: 0.20-0.93,
= 0.031).
The evidence supports NANOG as a tumor biomarker to guide clinical management and indicate prognosis. Additional studies are needed to further validate these results.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S169593</identifier><identifier>PMID: 30233213</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Analysis ; Anopheles ; Breast cancer ; Cancer ; Cancer metastasis ; Cancer research ; Cervical cancer ; Colorectal cancer ; Esophagus ; Gastric cancer ; Infrastructure (Economics) ; Liver cancer ; Lung cancer ; Lymphatic system ; Medical prognosis ; Medical research ; Meta-analysis ; Metastasis ; Oncology ; Ovarian cancer ; Prognosis ; Proteins ; Quality ; Review ; Stem cells ; Studies ; Survival analysis ; Transcription factors ; Tumors</subject><ispartof>OncoTargets and therapy, 2018-01, Vol.11, p.5515-5526</ispartof><rights>COPYRIGHT 2018 Dove Medical Press Limited</rights><rights>2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Zhao et al. This work is published and licensed by Dove Medical Press Limited 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-eb55469719d54ba18515f2fba9c63f05911fe03fb4d185db28bf7e7567cdb2143</citedby><orcidid>0000-0002-4234-0148 ; 0000-0002-6990-2745 ; 0000-0003-2718-7701 ; 0000-0002-8051-8250 ; 0000-0003-3131-3651 ; 0000-0003-2877-6452</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134963/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134963/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3849,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30233213$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Lingqiong</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Chen, Shu</creatorcontrib><creatorcontrib>Fang, Chun</creatorcontrib><creatorcontrib>Zhang, Xianquan</creatorcontrib><creatorcontrib>Luo, Zhibin</creatorcontrib><title>Prognostic significance of NANOG expression in solid tumors: a meta-analysis</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>NANOG is a tumor marker and indicates poor prognosis in various neoplasms; however, the evidence is controversial. This meta-analysis investigated the association of NANOG expression and clinicopathological features, and it impact on survival of patients with malignant tumors.
Studies published through May 31, 2018 were retrieved from PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure. Two researchers independently screened the content and quality of studies and extracted data. Correlations of NANOG expression, clinicopathological variables, and survival were analyzed and the combined odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated.
Thirty-three articles including 35 data sets of 3,959 patients were analyzed. Overall, elevated NANOG expression was associated with poor overall survival (HR = 2.19; 95% CI: 1.87-2.58,
<0.001) and poor disease-free survival (HR = 2.21, 95% CI: 1.54-3.18,
<0.001). Subgroup analysis found that NANOG expression was associated with worse overall survival in non-small cell lung (HR = 1.87; 95% CI: 1.26-2.76,
= 0.002), head and neck (HR = 2.29; 95% CI: 1.75-3.02,
<0.001), and digestive system (HR = 2.38; 95% CI: 1.95-2.91,
<0.001) cancers. Moreover, we found that high NANOG expression was associated with poor tumor differentiation (OR = 2.63; 95% CI: 1.59-4.55,
= 0.001), lymph node metastasis (OR = 2.59; 95% CI: 1.50-4.47,
= 0.001), advanced TNM stage (OR = 2.22; 95% CI: 1.42-3.45,
<0.001), and T stage (OR = 0.44; 95% CI: 0.20-0.93,
= 0.031).
The evidence supports NANOG as a tumor biomarker to guide clinical management and indicate prognosis. Additional studies are needed to further validate these results.</description><subject>Analysis</subject><subject>Anopheles</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer metastasis</subject><subject>Cancer research</subject><subject>Cervical cancer</subject><subject>Colorectal cancer</subject><subject>Esophagus</subject><subject>Gastric cancer</subject><subject>Infrastructure (Economics)</subject><subject>Liver cancer</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Meta-analysis</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Quality</subject><subject>Review</subject><subject>Stem cells</subject><subject>Studies</subject><subject>Survival analysis</subject><subject>Transcription factors</subject><subject>Tumors</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkl1rFDEUhgdRbK1eeS8BoQgy6-RzJl4UllJbYekKrtchkznZTZlJ1mRG7L9vSrfLrphc5OM85w055y2K97iaEczqL8vVavYTC8klfVGcYlw3pZC0enmwPynepHRXVUI0hL0uTmhFKCWYnhaLHzGsfUijMyi5tXfWGe0NoGDR7fx2eY3g7zZCSi545DxKoXcdGqchxPQVaTTAqEvtdX-fXHpbvLK6T_But54Vv75drS5vysXy-vvlfFEaXtOxhJZzJmSNZcdZq3HDMbfEtloaQW3FJcYWKmpb1uVY15KmtTXUXNQmHzCjZ8XFk-52agfoDPgx6l5toxt0vFdBO3Uc8W6j1uGPEpgyKWgW-LQTiOH3BGlUg0sG-l57CFNSBOfBOKY4ox__Qe_CFPOHM0UYbkRDs-KeWuselPM25HfNo6ia84YKyWRDMjX7D5VnB4MzwYN1-f4o4fwgYQO6Hze5A9OYu5GOwc9PoIkhpQh2XwxcqUeXqOwStXNJpj8c1m_PPtuCPgARC7Vp</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Zhao, Lingqiong</creator><creator>Liu, Jie</creator><creator>Chen, Shu</creator><creator>Fang, Chun</creator><creator>Zhang, Xianquan</creator><creator>Luo, Zhibin</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4234-0148</orcidid><orcidid>https://orcid.org/0000-0002-6990-2745</orcidid><orcidid>https://orcid.org/0000-0003-2718-7701</orcidid><orcidid>https://orcid.org/0000-0002-8051-8250</orcidid><orcidid>https://orcid.org/0000-0003-3131-3651</orcidid><orcidid>https://orcid.org/0000-0003-2877-6452</orcidid></search><sort><creationdate>20180101</creationdate><title>Prognostic significance of NANOG expression in solid tumors: a meta-analysis</title><author>Zhao, Lingqiong ; Liu, Jie ; Chen, Shu ; Fang, Chun ; Zhang, Xianquan ; Luo, Zhibin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-eb55469719d54ba18515f2fba9c63f05911fe03fb4d185db28bf7e7567cdb2143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Analysis</topic><topic>Anopheles</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer metastasis</topic><topic>Cancer research</topic><topic>Cervical cancer</topic><topic>Colorectal cancer</topic><topic>Esophagus</topic><topic>Gastric cancer</topic><topic>Infrastructure (Economics)</topic><topic>Liver cancer</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Meta-analysis</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Quality</topic><topic>Review</topic><topic>Stem cells</topic><topic>Studies</topic><topic>Survival analysis</topic><topic>Transcription factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Lingqiong</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Chen, Shu</creatorcontrib><creatorcontrib>Fang, Chun</creatorcontrib><creatorcontrib>Zhang, Xianquan</creatorcontrib><creatorcontrib>Luo, Zhibin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Lingqiong</au><au>Liu, Jie</au><au>Chen, Shu</au><au>Fang, Chun</au><au>Zhang, Xianquan</au><au>Luo, Zhibin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of NANOG expression in solid tumors: a meta-analysis</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>11</volume><spage>5515</spage><epage>5526</epage><pages>5515-5526</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>NANOG is a tumor marker and indicates poor prognosis in various neoplasms; however, the evidence is controversial. This meta-analysis investigated the association of NANOG expression and clinicopathological features, and it impact on survival of patients with malignant tumors.
Studies published through May 31, 2018 were retrieved from PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure. Two researchers independently screened the content and quality of studies and extracted data. Correlations of NANOG expression, clinicopathological variables, and survival were analyzed and the combined odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated.
Thirty-three articles including 35 data sets of 3,959 patients were analyzed. Overall, elevated NANOG expression was associated with poor overall survival (HR = 2.19; 95% CI: 1.87-2.58,
<0.001) and poor disease-free survival (HR = 2.21, 95% CI: 1.54-3.18,
<0.001). Subgroup analysis found that NANOG expression was associated with worse overall survival in non-small cell lung (HR = 1.87; 95% CI: 1.26-2.76,
= 0.002), head and neck (HR = 2.29; 95% CI: 1.75-3.02,
<0.001), and digestive system (HR = 2.38; 95% CI: 1.95-2.91,
<0.001) cancers. Moreover, we found that high NANOG expression was associated with poor tumor differentiation (OR = 2.63; 95% CI: 1.59-4.55,
= 0.001), lymph node metastasis (OR = 2.59; 95% CI: 1.50-4.47,
= 0.001), advanced TNM stage (OR = 2.22; 95% CI: 1.42-3.45,
<0.001), and T stage (OR = 0.44; 95% CI: 0.20-0.93,
= 0.031).
The evidence supports NANOG as a tumor biomarker to guide clinical management and indicate prognosis. Additional studies are needed to further validate these results.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>30233213</pmid><doi>10.2147/OTT.S169593</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-4234-0148</orcidid><orcidid>https://orcid.org/0000-0002-6990-2745</orcidid><orcidid>https://orcid.org/0000-0003-2718-7701</orcidid><orcidid>https://orcid.org/0000-0002-8051-8250</orcidid><orcidid>https://orcid.org/0000-0003-3131-3651</orcidid><orcidid>https://orcid.org/0000-0003-2877-6452</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2018-01, Vol.11, p.5515-5526 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6134963 |
| source | Taylor & Francis Open Access; DOVE Medical Press Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Analysis Anopheles Breast cancer Cancer Cancer metastasis Cancer research Cervical cancer Colorectal cancer Esophagus Gastric cancer Infrastructure (Economics) Liver cancer Lung cancer Lymphatic system Medical prognosis Medical research Meta-analysis Metastasis Oncology Ovarian cancer Prognosis Proteins Quality Review Stem cells Studies Survival analysis Transcription factors Tumors |
| title | Prognostic significance of NANOG expression in solid tumors: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T19%3A24%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20NANOG%20expression%20in%20solid%20tumors:%20a%20meta-analysis&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Zhao,%20Lingqiong&rft.date=2018-01-01&rft.volume=11&rft.spage=5515&rft.epage=5526&rft.pages=5515-5526&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S169593&rft_dat=%3Cgale_pubme%3EA583694982%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2241868396&rft_id=info:pmid/30233213&rft_galeid=A583694982&rfr_iscdi=true |